Diroximel Fumarate is an oral fumarate ester prodrug indicated for the treatment of relapsing forms of multiple sclerosis in adults. As a therapeutic agent, it is rapidly hydrolyzed in the body to its… Read more






![Chemical structure of 2-{4-[2-(2,5-Dioxopyrrolidin-1-yl)ethoxy]-4-oxobutanamido}ethyl methyl (2E)-but-2-enedioate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2-4-2-25-Dioxopyrrolidin-1-ylethoxy-4-oxobutanamidoethyl-methyl-2E-but-2-enedioate.png&w=3840&q=75)







Diroximel Fumarate is an oral fumarate ester prodrug indicated for the treatment of relapsing forms of multiple sclerosis in adults. As a therapeutic agent, it is rapidly hydrolyzed in the body to its active metabolite, monomethyl fumarate, which modulates pathways associated with oxidative stress and inflammation. Laboratories utilize our comprehensive range of Diroximel Fumarate reference standards, related impurities, and stable isotope-labelled compounds to support rigorous analytical testing and quality control protocols. These high-quality materials are essential for accurate impurity profiling, method validation, and the development of reliable stability-indicating assays throughout the pharmaceutical manufacturing and research lifecycle. By incorporating these precision compounds into analytical workflows, researchers can ensure compliance with regulatory standards and maintain consistent product quality during the synthesis and evaluation of this immunomodulatory therapy.